Park Square Financial Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-789
Closed -$65.4K – 972
2025
Q2
$65.4K Buy
789
+3
+0.4% +$239 0.05% 262
2025
Q1
$63.7K Sell
786
-295
-27% -$26.4K 0.05% 234
2024
Q4
$97.3K Buy
+1,081
New +$105K 0.07% 186

Other funds holding XBI

Park Square Financial Group's XBI Position: Q3 2025 in Review

Park Square Financial Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2025, closing a stake of 789 shares — an estimated $65.4K sold.

Park Square Financial Group first reported a position in XBI in Q4 2024 and held it in 3 quarters. The position peaked at $97.3K in Q4 2024. 656 funds tracked by Wall St. Rank hold XBI as of Q3 2025.

  • Park Square Financial Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2025 after selling out during the quarter.
  • Park Square Financial Group sold 789 State Street SPDR S&P Biotech ETF shares in Q3 2025, an estimated $65.4K.
  • Park Square Financial Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and held it in 3 quarters.
  • Park Square Financial Group's State Street SPDR S&P Biotech ETF position peaked at $97.3K in Q4 2024.
  • 656 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2025.

Based on Park Square Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.